NorthStar Medical Radioisotopes has entered an agreement to supply actinium-225 (Ac-225) to Athens, Greece-based contract research organization Bioemtech.
The supply agreement will allow Bioemtech to provide its customers with consistent access to Ac-225 for use in preclinical studies using its imaging platforms. Bioemtech is a preclinical radiopharmaceutical-focused contract research organization that also designs and manufactures high-resolution PET and SPECT imaging systems for preclinical and translational research.
Ac-225 is an alpha-emitting radioisotope used in targeted alpha therapy, a radiopharmaceutical therapy that delivers highly potent radiation directly to cancer cells. Initial deliveries will begin in the first quarter of 2026, with scalable volumes based on research demand, the companies noted.
